{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:03:23Z","timestamp":1784588603058,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Richard and Edith Strauss Foundation"},{"name":"Aclon Foundation"},{"DOI":"10.13039\/100013367","name":"Fondation Jean-Louis L\u00e9vesque","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013367","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Montreal Roger Des Groseillers Chair in Surgical Oncology"},{"name":"Fonds de recherche du Qu\u00e9bec-Sant\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02981-8","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T12:52:56Z","timestamp":1779713576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gender differences in the plasma profiles of proprotein convertase subtilisin\/kexin-type 9 (PCSK9), soluble low-density lipoprotein receptor (sLDLR), total cholesterol, and triglycerides in patients with colorectal cancer liver metastases: diagnostic and prognostic implications"],"prefix":"10.1186","volume":"25","author":[{"given":"Clara","family":"Lafortune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczyslaw","family":"Marcinkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majambu","family":"Mbikay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2981_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022\u201336.","journal-title":"Circ Res"},{"key":"2981_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/1753-0407.12064","volume":"5","author":"M Mbikay","year":"2013","unstructured":"Mbikay M, Mayne J, Chr\u00e9tien M. Proprotein convertases subtilisin\/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions. J Diabetes. 2013;5:391\u2013405.","journal-title":"J Diabetes"},{"key":"2981_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/s41467-021-22167-3","volume":"12","author":"A Alabi","year":"2021","unstructured":"Alabi A, Xia XD, Gu HM, Wang F, Deng SJ, Yang N, et al. Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis. Nat Commun. 2021;12:1889.","journal-title":"Nat Commun"},{"key":"2981_CR4","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.atherosclerosis.2023.06.246","volume":"379","author":"M Zegeye","year":"2023","unstructured":"Zegeye M, Ljungberg L, Nakka S, Andersson J, S\u00f6derberg S, Kumawat A, et al. Soluble LDL-receptor is induced by TNF-\u0391 and inhibits hepatocytic clearance of LDL-cholesterol. Atherosclerosis. 2023;379:S61.","journal-title":"Atherosclerosis"},{"key":"2981_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","volume":"51","author":"G Dubuc","year":"2010","unstructured":"Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140\u20139.","journal-title":"J Lipid Res"},{"key":"2981_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jcla.21727","volume":"29","author":"H Shimohiro","year":"2015","unstructured":"Shimohiro H, Taniguchi S, Koda M, Sakai C, Yamada S. Association between serum soluble low-density lipoprotein receptor levels and metabolic factors in healthy Japanese individuals. J Clin Lab Anal. 2015;29:52\u20136.","journal-title":"J Clin Lab Anal"},{"key":"2981_CR7","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1210\/jc.2018-00777","volume":"103","author":"J Mayne","year":"2018","unstructured":"Mayne J, Ooi TC, Tepliakova L, Seebun D, Walker K, Mohottalage D, et al. Associations between soluble LDLR and lipoproteins in a White cohort and the effect of PCSK9 loss-of-function. J Clin Endocrinol Metab. 2018;103:3486\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"2981_CR8","doi-asserted-by":"publisher","first-page":"100503","DOI":"10.1016\/j.jlr.2024.100503","volume":"65","author":"RM Krauss","year":"2024","unstructured":"Krauss RM, Fisher LM, King SM, Gardner CD. Changes in soluble LDL receptor and lipoprotein fractions in response to diet in the DIETFITS weight loss study. J Lipid Res. 2024;65:100503.","journal-title":"J Lipid Res"},{"key":"2981_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bbrc.2007.07.029","volume":"361","author":"J Mayne","year":"2007","unstructured":"Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun. 2007;361:451\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"2981_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","volume":"309","author":"N Ferri","year":"2020","unstructured":"Ferri N, Ruscica M, Coggi D, Bonomi A, Amato M, Frigerio B, et al. Gender-specific predictors of PCSK9 levels in a European population: the IMPROVE study. Atherosclerosis. 2020;309:39\u201346.","journal-title":"Atherosclerosis"},{"key":"2981_CR11","doi-asserted-by":"publisher","first-page":"953845","DOI":"10.3389\/fphar.2022.953845","volume":"13","author":"F Jia","year":"2022","unstructured":"Jia F, Fei SF, Tong DB, Xue C, Li JJ. Gender difference in circulating PCSK9 and its clinical implications. Front Pharmacol. 2022;13:953845.","journal-title":"Front Pharmacol"},{"key":"2981_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"2981_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","volume":"24","author":"H Wang","year":"2024","unstructured":"Wang H, Zhang X, Zhang Y, Shi T, Zhang Y, Song X, et al. Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy. BMC Cancer. 2024;24:445.","journal-title":"BMC Cancer"},{"key":"2981_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","volume":"12","author":"J Yuan","year":"2021","unstructured":"Yuan J, Cai T, Zheng X, Ren Y, Qi J, Lu X, et al. Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12:240\u201360.","journal-title":"Protein Cell"},{"key":"2981_CR15","doi-asserted-by":"publisher","first-page":"e18018","DOI":"10.7717\/peerj.18018","volume":"12","author":"Y Xu","year":"2024","unstructured":"Xu Y, Xu Y, Yang Y, Zhang Z, Xiong Q, Zhu Q. Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. PeerJ. 2024;12:e18018.","journal-title":"PeerJ"},{"key":"2981_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1759-7714.14259","volume":"13","author":"M Xie","year":"2022","unstructured":"Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J, et al. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer. 2022;13:353\u201360.","journal-title":"Thorac Cancer"},{"key":"2981_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41416-021-01667-5","volume":"126","author":"N Messaoudi","year":"2022","unstructured":"Messaoudi N, Henault D, Stephen D, Cousineau I, Simoneau E, Rong Z, et al. Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns. Br J Cancer. 2022;126:1329\u201338.","journal-title":"Br J Cancer"},{"key":"2981_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-511X-12-70","volume":"12","author":"J Mayne","year":"2013","unstructured":"Mayne J, Ooi TC, Raymond A, Cousins M, Bernier L, Dewpura T, et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 2013;12:70.","journal-title":"Lipids Health Dis"},{"key":"2981_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128650","author":"PF Lebeau","year":"2021","unstructured":"Lebeau PF, Wassef H, Byun JH, Platko K, Ason B, Jackson S, et al. The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI128650.","journal-title":"J Clin Invest"},{"key":"2981_CR20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1139\/o2012-031","volume":"90","author":"M Chr\u00e9tien","year":"2012","unstructured":"Chr\u00e9tien M. My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. Biochem Cell Biol. 2012;90:750\u201368.","journal-title":"Biochem Cell Biol"},{"key":"2981_CR21","doi-asserted-by":"publisher","first-page":"e14721","DOI":"10.14814\/phy2.14721","volume":"9","author":"Y Cyr","year":"2021","unstructured":"Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, et al. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiol Rep. 2021;9:e14721.","journal-title":"Physiol Rep"},{"key":"2981_CR22","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1038\/oncsis.2015.49","volume":"5","author":"S Beloribi-Djefaflia","year":"2016","unstructured":"Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189.","journal-title":"Oncogenesis"},{"key":"2981_CR23","doi-asserted-by":"publisher","first-page":"682911","DOI":"10.3389\/fonc.2021.682911","volume":"11","author":"I Giacomini","year":"2021","unstructured":"Giacomini I, Gianfanti F, Desbats MA, Orso G, Berretta M, Prayer-Galetti T, et al. Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy. Front Oncol. 2021;11:682911.","journal-title":"Front Oncol"},{"key":"2981_CR24","doi-asserted-by":"publisher","first-page":"1134063","DOI":"10.3389\/fonc.2023.1134063","volume":"13","author":"C Sun","year":"2023","unstructured":"Sun C, Zhu G, Shen C, Huang S, Li R, Li J, et al. Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis. Front Oncol. 2023;13:1134063.","journal-title":"Front Oncol"},{"key":"2981_CR25","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","volume":"13","author":"CC Wong","year":"2022","unstructured":"Wong CC, Wu JL, Ji F, Kang W, Bian X, Chen H, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer. Nat Commun. 2022;13:3971.","journal-title":"Nat Commun"},{"key":"2981_CR26","doi-asserted-by":"publisher","first-page":"947756","DOI":"10.3389\/fimmu.2022.947756","volume":"13","author":"R Wang","year":"2022","unstructured":"Wang R, Liu H, He P, An D, Guo X, Zhang X, et al. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells. Front Immunol. 2022;13:947756.","journal-title":"Front Immunol"},{"key":"2981_CR27","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/cvr\/cvad041","volume":"119","author":"M Laudette","year":"2023","unstructured":"Laudette M, Lindbom M, Arif M, Cinato M, Ruiz M, Doran S, et al. Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovasc Res. 2023;119:1537\u201352.","journal-title":"Cardiovasc Res"},{"key":"2981_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646\u201354.","journal-title":"Hepatology"},{"key":"2981_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/jso.26361","volume":"123","author":"C Kamphues","year":"2021","unstructured":"Kamphues C, Andreatos N, Kruppa J, Buettner S, Wang J, Sasaki K, et al. The optimal cut-off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver metastases: an international, multi-institutional study. J Surg Oncol. 2021;123:939\u201348.","journal-title":"J Surg Oncol"},{"key":"2981_CR30","unstructured":"The Human Protein Atlas: PCSK9 expression and localization. 2023. https:\/\/www.proteinatlas.org\/ENSG00000169174-PCSK9."},{"key":"2981_CR31","unstructured":"The Human Protein Atlas: LDLR expression and localization. 2023. https:\/\/www.proteinatlas.org\/ENSG00000130164-LDLR\/tissue."},{"key":"2981_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/febs.16923","volume":"291","author":"MI Saad","year":"2024","unstructured":"Saad MI, Jenkins BJ. The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond. FEBS J. 2024;291:10\u201324.","journal-title":"FEBS J"},{"key":"2981_CR33","doi-asserted-by":"publisher","first-page":"717606","DOI":"10.3389\/fonc.2021.717606","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Li S, Zhou L, Yang L, Wu X, Tang B, et al. Immune infiltration of MMP14 in pan cancer and its prognostic effect on tumors. Front Oncol. 2021;11:717606.","journal-title":"Front Oncol"},{"key":"2981_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjaf001","author":"Z Li","year":"2025","unstructured":"Li Z, Fan K, Suo C, Gu X, Zhu C, Wei H, et al. ENO1-BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism. J Mol Cell Biol. 2025. https:\/\/doi.org\/10.1093\/jmcb\/mjaf001.","journal-title":"J Mol Cell Biol"},{"key":"2981_CR35","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202202011","author":"F Bonacina","year":"2022","unstructured":"Bonacina F, Moregola A, Svecla M, Coe D, Uboldi P, Fraire S, et al. The low-density lipoprotein receptor-mTORC1 axis coordinates CD8+ T cell activation. J Cell Biol. 2022. https:\/\/doi.org\/10.1083\/jcb.202202011.","journal-title":"J Cell Biol"},{"key":"2981_CR36","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.7150\/ijbs.93668","volume":"20","author":"W Xu","year":"2024","unstructured":"Xu W, Hu M, Lu X, Lao Y, Ma N, Wang Y, et al. Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy. Int J Biol Sci. 2024;20:3942\u201355.","journal-title":"Int J Biol Sci"},{"key":"2981_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132\u201341.","journal-title":"Nat Metab"},{"key":"2981_CR38","doi-asserted-by":"publisher","first-page":"57290","DOI":"10.18632\/oncotarget.10145","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang ZQ, Wang FH, Lei XF, Yan SM, Wang DS, et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget. 2016;7:57290\u2013300.","journal-title":"Oncotarget"},{"key":"2981_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12944-020-1199-9","volume":"19","author":"M Mbikay","year":"2020","unstructured":"Mbikay M, Mayne J, Chr\u00e9tien M. The enigma of soluble LDLR: could inflammation be the key? Lipids Health Dis. 2020;19:17.","journal-title":"Lipids Health Dis"},{"key":"2981_CR40","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1111\/jcmm.16349","volume":"25","author":"H Yin","year":"2021","unstructured":"Yin H, Li W, Mo L, Deng S, Lin W, Ma C, et al. Adipose triglyceride lipase promotes the proliferation of colorectal cancer cells via enhancing the lipolytic pathway. J Cell Mol Med. 2021;25:3963\u201375.","journal-title":"J Cell Mol Med"},{"key":"2981_CR41","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1111\/ans.17835","volume":"92","author":"GYM Wong","year":"2022","unstructured":"Wong GYM, Mol B, Bhimani N, de Reuver P, Diakos C, Molloy MP, et al. Recurrence patterns predict survival after resection of colorectal liver metastases. ANZ J Surg. 2022;92:2149\u201356.","journal-title":"ANZ J Surg"},{"key":"2981_CR42","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94:2537\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"2981_CR43","doi-asserted-by":"publisher","first-page":"117108","DOI":"10.1016\/j.atherosclerosis.2023.03.013","volume":"384","author":"AMH Galema-Boers","year":"2023","unstructured":"Galema-Boers AMH, Mulder J, Steward K, Roeters van Lennep JE. Gender differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry. Atherosclerosis. 2023;384:117108.","journal-title":"Atherosclerosis"},{"key":"2981_CR44","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1194\/jlr.M061952","volume":"56","author":"A Roubtsova","year":"2015","unstructured":"Roubtsova A, Chamberland A, Marcinkiewicz J, Essalmani R, Fazel A, Bergeron JJ, et al. PCSK9 deficiency unmasks a gender- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J Lipid Res. 2015;56:2133\u201342.","journal-title":"J Lipid Res"},{"key":"2981_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2022.159217","author":"A Roubtsova","year":"2022","unstructured":"Roubtsova A, Garcon D, Lacoste S, Chamberland A, Marcinkiewicz J, Metivier R, et al. PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: role of hepatic cholesterol. Biochim Biophys Acta (BBA). 2022. https:\/\/doi.org\/10.1016\/j.bbalip.2022.159217.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"2981_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12964-024-01582-1","volume":"22","author":"G Topi","year":"2024","unstructured":"Topi G, Satapathy SR, Ghatak S, Hellman K, Ek F, Olsson R, et al. High oestrogen receptor alpha expression correlates with adverse prognosis and promotes metastasis in colorectal cancer. Cell Commun Signal. 2024;22:198.","journal-title":"Cell Commun Signal"},{"key":"2981_CR47","doi-asserted-by":"publisher","first-page":"739620","DOI":"10.3389\/fmed.2022.739620","volume":"9","author":"G Topi","year":"2022","unstructured":"Topi G, Ghatak S, Satapathy SR, Ehrnstrom R, Lydrup ML, Sjolander A. Combined estrogen alpha and beta receptor expression has a prognostic significance for colorectal cancer patients. Front Med (Lausanne). 2022;9:739620.","journal-title":"Front Med (Lausanne)"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02981-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:34:44Z","timestamp":1784586884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02981-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2981"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02981-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7420891\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval for the study was obtained from the Research Ethics Committees of IRCM (no. CAP9SLD) and CHUM (no. 16.262). Participants were adult volunteers who were informed about the study's objectives and the terms of confidentiality and provided written informed consent prior to participation. The study adhered to the principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"169"}}